Genting New Dawn berencana mengakuisisi perusahaan Singapura Heisen Pharmaceutical sebesar 250 juta dolar AS, dengan pendapatan tahun lalu meningkat sebesar 142%

Rui Cai Jing Yan Ming Hui 8 April, Genting New Dawn (01952.HK) announced that its wholly owned subsidiary in Singapore, EverSea Medicines (Singapore) Pte. Ltd., has signed an equity purchase agreement with Haisen Biopharmaceuticals (Asia) Limited, intending to acquire all shares of its wholly owned subsidiary, Haisen Biopharmaceuticals (Singapore) Limited. The total transaction consideration is USD 250 million (approximately RMB 1.722 billion), to be paid in three installments, subject to the fulfillment or waiver of relevant conditions precedent for each payment.

After the completion of the transaction, Haisen Biopharmaceuticals (Singapore) Limited will become an indirect wholly owned subsidiary of Genting New Dawn, and its financial performance will be consolidated into the company’s financial statements.

According to Genting New Dawn’s 2025 annual performance report, the company’s annual revenue increased by 142% year-on-year to RMB 1.707 billion, achieving a turnaround from loss to profit under non-IFRS standards for the first time, recording a profit of RMB 187 million. Under IFRS standards, the loss also significantly narrowed by 71%, and operating cash flow turned positive.

The chairman of the board is Wu Yifang, who was formerly chairman of Fosun Pharma and has over 35 years of experience in the biopharmaceutical industry.

Related company: Genting New Dawn HK01952